| Withdrawn | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, an NCT07490301 | AbbVie | Phase 2 / Phase 3 |
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metas NCT07441174 | InxMed (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12 NCT07259590 | Genfleet Therapeutics (Shanghai) Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced NCT07198321 | Genfleet Therapeutics (Shanghai) Inc. | Phase 1 / Phase 2 |
| Recruiting | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Pat NCT07145450 | Anocca AB | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors NCT07014878 | Beijing DCTY Biotech Co.,Ltd. | Phase 1 |
| Recruiting | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Aden NCT06625320 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreat NCT06515587 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals NCT06122896 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Not Yet Recruiting | Mesopancreas Study in Pancreatic Cancer NCT05895214 | Heinrich-Heine University, Duesseldorf | — |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Active Not Recruiting | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05642962 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer NCT05355298 | Amplia Therapeutics Limited | Phase 1 / Phase 2 |
| Unknown | 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma NCT05275985 | Peking Union Medical College Hospital | N/A |
| Recruiting | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer NCT06151223 | Mayo Clinic | — |
| Unknown | Pancreatic Cancer Recurrence in the Netherlands NCT04605237 | UMC Utrecht | — |